abstract |
Disclosed is the use of an antagonist of IL-23 for the manufacture of a medicament for the treatment of tumors comprising tumor cells, wherein the antagonist of IL-23 comprises an antibody, or antigen binding fragment thereof, that specifically binds to IL-23R (SEQ ID NO: 6). Also disclosed are methods of determining whether tumors express IL-23 receptor. (62) Divided Out of 541898 |